NASDAQ$TWST
Twist Bioscience Corporation · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported revenue increase of 49% year-over-year and reached a settlement agreement with Agilent in litigation.
Twist Bioscience reported a strong start to fiscal year 2020, with revenues of $17.2 million, a 49% increase over the same period last year. The company also reached a settlement agreement with Agilent, removing uncertainty and paving the way for future growth.
- Total orders received for the first quarter of fiscal 2020 were $24.8 million, compared to $15.2 million for the same period of fiscal 2019.
- Total revenues were $17.2 million for the first quarter of fiscal 2020 compared to $11.5 million for the same period of fiscal 2019.
- Shipped products to approximately 1,000 customers in the first quarter of fiscal 2020, versus about 600 in the same period of fiscal 2019.
- Signed a collaboration with Schrödinger, Inc. to discover new antibody therapeutics against G-protein coupled receptor (GPCR) targets.
Headline financials
Revenue & EPS history
Twist Bioscience · Revenue · Quarterly
$17.2M
Revenue by segment
Twist Bioscience · $218M total across 2 segments · Q3 2023
- NGS Applications$120M+23.7%55.0%
- DNA Synthesis & Protein$98M+22.5%45.0%
Forward guidance
Twist Bioscience provided updated financial guidance for the full fiscal year 2020.
Tailwinds
- Revenue expected in the range of $80 to $84 million consistent with our previous guidance
- Revenue from Ginkgo Bioworks expected to be approximately $10 million
- Synbio revenue excluding Ginkgo Bioworks is expected to be in the range of $32 to $33 million
- NGS revenue is estimated to be in the range of $37 to $40 million
- Biopharma revenue is estimated to be approximately $1.0
Headwinds
- Gross margin is expected to be approximately 32% for fiscal 2020
- Net loss (Excluding Litigation Settlement) is expected in the range of $107 million to $110 million, an increase from our previous guidance of $103 to $106 million primarily due to legal fees associated with the Agilent litigation in anticipation of a trial beginning February 24, 2020.
- Net loss (Including Litigation Settlement) expected in the range of $129.5 to $132.5 million.
- Legal fees associated with the Agilent litigation
- Uncertainty of the litigation removed
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+0.1%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+0.8%
Avg return
30 days after
47%
14 / 30 earnings
Positive
+29.7%
Q4 2023
Best reaction
-23.2%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -7.3% | -5.9% | +19.6% | |
| Q1 2026 | +13.8% | -5.9% | -10.2% | |
| Q4 2025 | -10.0% | -14.9% | +3.4% | |
| Q2 2025 | -8.5% | -16.9% | -20.8% | |
| Q1 2025 | +0.7% | -0.1% | -19.7% | |
| Q4 2024 | +12.0% | +14.5% | +20.9% | |
| Q3 2024 | -14.6% | -16.0% | -18.5% | |
| Q2 2024 | +28.9% | +34.9% | +31.1% | |
| Q1 2024 | +9.5% | +5.1% | +16.9% | |
| Q4 2023 | +29.7% | +24.9% | +81.5% | |
| Q3 2023 | +14.9% | +9.3% | +14.0% | |
| Q2 2023 | +3.6% | +2.1% | +26.0% | |
| Q1 2023 | -23.2% | -15.2% | -37.1% | |
| Q4 2022 | +0.8% | +0.5% | -0.6% | |
| Q3 2022 | +20.8% | +12.4% | -17.2% | |
| Q2 2022 | -9.9% | -16.3% | -12.6% | |
| Q1 2022 | -1.0% | +6.0% | -21.0% | |
| Q4 2021 | -12.6% | -14.1% | -22.4% | |
| Q3 2021 | -9.1% | -15.8% | -7.6% | |
| Q2 2021 | +6.2% | -9.4% | -12.4% | |
| Q1 2021 | -16.8% | -5.5% | -38.1% | |
| Q4 2020 | -9.9% | -0.8% | +44.3% | |
| Q3 2020 | -7.2% | -16.3% | -4.8% | |
| Q2 2020 | +5.1% | +4.6% | +0.7% | |
| Q1 2020 | +21.3% | +14.0% | +31.4% | |
| Q4 2019 | +4.6% | +5.8% | -15.5% | |
| Q3 2019 | -11.2% | -11.8% | -13.9% | |
| Q2 2019 | -9.9% | -9.7% | -3.9% | |
| Q1 2019 | -9.2% | -11.8% | -6.9% | |
| Q4 2018 | -9.2% | -9.4% | +18.6% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro